CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers
An Open-label, Un-controlled, Single-centre Trial Investigating the Efficacy and Safety of CRD007 in Children With Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD) or Children Being Symptomatic Carriers for DMD or BMD
1 other identifier
interventional
N/A
1 country
1
Brief Summary
This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 23, 2012
CompletedFirst Posted
Study publicly available on registry
February 29, 2012
CompletedOctober 2, 2012
October 1, 2012
February 23, 2012
October 1, 2012
Conditions
Keywords
Study Arms (1)
CRD007 10 mg tablet
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Documented diagnosis of dystrophinopathy
You may not qualify if:
- Severe functional impairment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- RSPR Pharma ABlead
Study Sites (1)
Unknown Facility
Stockholm, Sweden
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
T Sejersen, MD PhD
Karolinska University Hospital
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 23, 2012
First Posted
February 29, 2012
Last Updated
October 2, 2012
Record last verified: 2012-10